Tirzepatide
Dual GIP / GLP-1 Agonist
- Form
- Lyophilized powder
- Storage
- -20°C (lyophilized)
- Origin
- USA lab
from$99
Tirzepatide is a synthetic peptide reference material used in laboratory investigations of GIP and GLP-1 receptor activity and dual-receptor signaling mechanisms.
- Dual GIP/GLP-1 receptor research
- Receptor activation and downstream signaling studies
- In-vitro metabolic pathway models
SKU: AP-TIRZ-10MG
3 vial minimum per order — mix any products
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Reconstitution ReferenceOptional — how strong is the mixed vial?
Mixing a powder vial with water? Fill in the fields — results update as you type.
Mixing 10 mg of peptide into 2 mL of water makes a 5 mg/mL solution. Each 0.1 mL contains 0.5 mg.
Reference for in-vitro laboratory handling only. Outputs describe the physical properties of the reconstituted vial (concentration and mass drawn) — they are not dosing guidance, administration instructions, or medical advice. Verify all measurements independently.
The science behind Tirzepatide
A structured overview of the published literature surrounding tirzepatide as a dual GIP/GLP-1 receptor research compound.
Tirzepatide is a synthetic peptide engineered to engage two incretin receptors — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is studied in the research setting as a dual-agonist reference compound.
The dual-receptor design has made tirzepatide a heavily referenced tool in metabolic-signaling research, where investigators use it to probe how simultaneous GIP and GLP-1 receptor activation differs from single-receptor agonism.
The material supplied here is intended solely as a laboratory reference standard, and the summaries below describe only findings reported in published research.
Tirzepatide emerged from research into multi-receptor incretin agonists, based on the hypothesis that co-activating GIP and GLP-1 receptors would produce signaling profiles distinct from GLP-1 agonism alone.
It is characterized across a growing body of receptor-pharmacology and preclinical metabolic literature and is frequently used as a comparator in dual- and triple-agonist research.
The mechanism of interest is simultaneous agonism at the GIP and GLP-1 receptors, both class-B GPCRs, with reported activation of cAMP-dependent signaling in cellular models expressing each receptor.
Investigators study how the balance of GIP versus GLP-1 receptor engagement influences downstream insulin-secretion and metabolic signaling in preclinical systems.
Dual-receptor assays
Used to compare GIP and GLP-1 receptor activation within a single reference compound.
Incretin signaling
Examined in cellular cAMP and insulin-secretion signaling models.
Metabolic models
Referenced in preclinical glucose-regulation and energy-balance research.
Comparative pharmacology
Studied alongside single-receptor agonists to characterize dual-agonism signatures.
What is tirzepatide?
A synthetic dual GIP/GLP-1 receptor agonist peptide supplied as a laboratory reference material for receptor-signaling research.
What kind of research references tirzepatide?
Receptor-pharmacology assays and preclinical metabolic models comparing dual-receptor activation with single-receptor agonism.
Is Tirzepatide approved for human or veterinary use?
No. Tirzepatide is not approved by the FDA or any regulatory authority for human or animal use. It is sold exclusively for in-vitro and laboratory research and is not for consumption.
How is the reference material characterized?
Each released lot is supplied as a lyophilized powder with a lot-specific certificate of analysis reporting HPLC purity of ≥ 99%. The certificate is tied to the specific released lot.
How should the compound be stored?
Lyophilized material is typically stored at -20°C, protected from light and moisture. Handling should follow standard laboratory practice for peptide reference materials. We do not provide reconstitution, dosing, or administration guidance.
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab (2018).
- Willard FS, et al. Tirzepatide pharmacology at the GIP and GLP-1 receptors. JCI Insight (2020).
Links open a curated peer-reviewed search on PubMed. Allpointe Bio Research is not affiliated with the cited authors or publishers.
Research-Use Statement
The information above is provided for educational and scientific-reference purposes only and summarizes findings reported in the published preclinical and in-vitro literature. It is not medical advice and does not describe outcomes, benefits, or applications for humans or animals. Tirzepatide is supplied strictly as a laboratory reference material for in-vitro and research use only — it is not a drug or supplement, is not approved for human or veterinary use, and is not for consumption. Allpointe Bio Research does not provide clinical, dosing, reconstitution, or administration guidance.